EMA Management Board Meets to Discuss New Location

News
Article

The agency met to discuss its new temporary and permanent premises in Amsterdam.

On Feb. 1, 2018, the Management Board of the European Medicines Agency met to discuss the agency’s future locations in Amsterdam. EMA will move from London to Amsterdam by the end of March 2019 and will move into a temporary residence until its new permanent location can be built.

The permanent location will be a new, tailor-made facility in the business district of Zuidas in Amsterdam. Details on the new, permanent location were given to the agency by the Dutch government. Because the building will not be complete by March 30, 2019, when EMA must relocate, a temporary location must be prepared. The agency stated in a press release that the temporary building, located in the Sloterdijk area, will be refurbished by January 1, 2019

The agency also discussed the dossier that will be submitted to the Budgetary Authority. EMA must gain a positive opinion from the Budgetary Authority before it can enter into a contractual obligation. EMA will gradually relocate staff to Amsterdam by the end of March 2019. 

Source: EMA

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.